Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study

Br J Dermatol. 2019 Nov;181(5):1078-1079. doi: 10.1111/bjd.18090. Epub 2019 Aug 5.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Arthralgia / diagnosis
  • Arthralgia / drug therapy*
  • Arthralgia / economics
  • Arthralgia / etiology
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / diagnosis
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / economics
  • Biosimilar Pharmaceuticals / administration & dosage*
  • Biosimilar Pharmaceuticals / adverse effects
  • Biosimilar Pharmaceuticals / economics
  • Cost Savings / statistics & numerical data
  • Etanercept / administration & dosage*
  • Etanercept / adverse effects
  • Etanercept / economics
  • Female
  • Humans
  • Injection Site Reaction / diagnosis
  • Injection Site Reaction / epidemiology
  • Injection Site Reaction / etiology
  • Male
  • Middle Aged
  • Pain Measurement
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / economics
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Biosimilar Pharmaceuticals
  • Etanercept